CVS Q2: the Aetna medical benefit ratio fell 2.5 points, and that is the whole print
CVS spent 2024 losing credibility on exactly this line. This is what regaining it looks like in numbers.
CVS Health reported second-quarter adjusted earnings of $2.58 per share, up from $1.81 a year earlier and well ahead of expectations, on revenue of about $106.1 billion. Full-year adjusted EPS guidance rose to $7.90–$8.10, an increase of 60 cents across the range.
One number explains almost all of it.
The medical benefit ratio is the whole trade
Aetna's medical benefit ratio fell to 87.4% from 89.9%. The company credits improved underlying performance in the government business and the absence of the premium deficiency reserve booked in the prior year.
The ratio is the share of premium paid out as medical cost, so every point off it drops close to directly into segment profit at this revenue scale. Moving it 2.5 points in a year is the difference between an insurer that is guessing at its cost trend and one that has caught up to it.
Note what the release itself separates: part of the improvement is real cost performance, and part is the absence of a one-time charge. Both are genuine, only one repeats.
The rest of the company did its job
Health Services and Pharmacy & Consumer Wellness both posted solid quarters, with prescription volume up roughly 7%. Operating cash flow guidance moved to at least $11.5 billion and the revenue outlook to at least $414 billion.
Why this print carries more weight than the number
CVS spent 2024 losing credibility on exactly this line. Medical costs ran ahead of pricing, guidance was cut, and the market stopped taking the outlook at face value.
Restoring that is a multi-quarter exercise, and it is not done by beating once. It is done by the cost trend, the plan ratings and the guidance all pointing the same way in the same release, which is what happened here.
Reported figures from the company's results release. Educational content, not financial advice.